Here's what we'll cover
Here's what we'll cover
If you're currently taking a GLP-1 medication or weighing your options, a headline about FDA leadership changes might feel unsettling. Here's the short version: your medication isn't going anywhere, but the longer-term implications for approvals, compounding access, and new drug availability are worth understanding.
What Actually Happened at the FDA
FDA Commissioner Marty Makary announced his resignation in May 2026. Kyle Diamantas, who served as the agency's top food regulator, is stepping in as acting commissioner during the transition period.
Leadership changes at the FDA are not unusual. The agency operates through career staff and established regulatory frameworks that continue regardless of who sits at the top. That said, a new acting commissioner can shift enforcement priorities, speed up or slow down rulemaking, and set the tone for how the agency handles emerging policy issues.
For GLP-1 patients, the most relevant policy areas that could be influenced include compounding pharmacy oversight, biosimilar approvals, and the pace of new drug reviews.
What This Does NOT Mean for Your Current Prescription
Let's be direct: if you are currently prescribed Ozempic, Wegovy, or Mounjaro, nothing about this news changes your medication status today.
FDA-approved drugs do not lose their approval because of a commissioner change. The approval process is built on scientific review by career staff, not political appointees. Semaglutide and tirzepatide have robust safety and efficacy records supported by large-scale clinical trials, and those records do not reset.
What can change under new leadership is how aggressively the agency enforces certain policies, how quickly new applications are reviewed, and how the agency communicates with the public and prescribers. Those are worth watching, but they are not a reason to stop or change your medication.
The Compounding Question Is Still Open
One of the most practically important FDA policy areas for GLP-1 patients right now involves compounded versions of semaglutide and tirzepatide.
Over the past two years, the FDA declared both semaglutide and tirzepatide to no longer be in shortage, which triggered enforcement action against compounding pharmacies producing copies of these drugs. That process has been contested in court and through industry lobbying, and it remains unsettled.
A new acting commissioner could take a harder or softer line on compounding enforcement. Patients who rely on compounded GLP-1s for cost reasons are watching this space closely, and rightly so.
If you are currently using a compounded version of semaglutide or tirzepatide, it is worth asking your provider about contingency options. Checking the GLP-1 Coupons page for manufacturer savings programs is also a smart move while the situation evolves.
Eli Lilly's New Weight Loss Drug Trials
Separate from the FDA leadership news, Eli Lilly is running clinical trials for next-generation weight loss compounds. This is a significant development for patients who are currently on tirzepatide (Mounjaro or Zepbound) or those who have not yet found the right fit.
Lilly's pipeline includes orforglipron, a once-daily oral GLP-1 receptor agonist that does not require injections. Phase 3 trial results have been promising, showing meaningful weight loss in participants. If approved, this would be the first oral GLP-1 option from a major manufacturer, which could substantially change the access and cost landscape.
There is also retatrutide, a triple-hormone receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Early trial data suggested weight loss exceeding 20% in some participants. These are not yet approved medications, but they represent the direction the field is moving.
Why This Matters for Access and Cost
A larger menu of FDA-approved options generally helps patients. More competition between manufacturers creates pressure on pricing. More formulations, including oral options, reduce barriers for people who are needle-averse or who struggle with injection-site reactions.
The timeline for these new drugs to reach pharmacy shelves depends significantly on how the FDA processes their applications. That makes the question of who is leading the agency, and with what priorities, genuinely relevant to patients.
How FDA Leadership Changes Affect Drug Approval Timelines
The FDA uses several pathways to approve new drugs faster when the evidence supports it. These include Priority Review, Breakthrough Therapy designation, and Accelerated Approval. Whether an acting commissioner prioritizes throughput and speed or takes a more cautious approach can shift how quickly new treatments become available.
Under prior administrations, GLP-1 drugs moved through the pipeline with relatively standard timelines. Semaglutide for weight management (Wegovy) received approval in 2021 after a Priority Review, following strong STEP trial data. Tirzepatide (Zepbound) followed in 2023.
Future approvals in this space will depend on both the quality of trial data and the regulatory environment at the time of submission. A stable, well-staffed FDA generally produces more predictable timelines.
What to Watch for in the Coming Months
There are a few specific developments worth tracking if you are a GLP-1 patient or considering starting treatment.
Compounding enforcement updates. Watch for any FDA announcements about compounding pharmacy guidance or enforcement actions related to semaglutide and tirzepatide. These could affect pricing and availability of lower-cost compounded versions.
New drug application filings. Lilly is expected to submit applications for orforglipron and potentially other pipeline compounds. The FDA's response timeline under new leadership will be informative.
Biosimilar developments. Biosimilar versions of semaglutide are in development at multiple companies. The FDA's handling of these applications will affect how quickly affordable alternatives reach patients.
Label expansion decisions. Semaglutide already received an expanded cardiovascular indication following the SELECT trial. Additional label expansions, such as for kidney disease, sleep apnea, or other conditions, could be in the pipeline and would affect insurance coverage.
These are not urgent action items for most patients. They are signals to watch over the next 6 to 18 months as the regulatory landscape develops.
What You Can Do Right Now as a Patient
The most practical step is to not change your medication based on regulatory news alone. Your prescriber has the full picture of your health history and should be your first call if you have concerns.
That said, this is a reasonable moment to make sure your access to medication is secure. Consider the following:
- Ask your provider whether your current prescription has refills available and plan ahead for any coverage gaps that could leave you without medication during a transition period
- If you use a compounded GLP-1, ask your pharmacy directly about their current regulatory status and any anticipated changes to their ability to compound semaglutide or tirzepatide
- Review your insurance coverage for the brand-name version of your medication in case compounded options become less accessible due to FDA enforcement shifts under new leadership
- Explore Best Providers if you are still in the process of finding a prescriber who can manage your GLP-1 treatment with proper clinical oversight and help navigate coverage complexities
The policy environment is shifting, but the underlying evidence for GLP-1 medications is not. These drugs have strong clinical backing and established prescribing infrastructure across the country.
No waiting list. No insurance needed.
Frequently Asked Questions
Will the FDA leadership change affect my Ozempic or Wegovy prescription?
No. FDA-approved medications like semaglutide and tirzepatide remain approved regardless of who leads the agency. Your current prescription is unaffected, and there is no reason to stop or change your medication based on this news.
What is the status of compounded semaglutide and tirzepatide in 2026?
The FDA has taken enforcement action against compounding pharmacies producing copies of semaglutide and tirzepatide following the end-of-shortage declarations. This situation remains legally contested. Patients using compounded versions should check with their pharmacy and discuss backup options with their provider.
Who is Kyle Diamantas and what does he oversee at the FDA?
Kyle Diamantas was the FDA's top food regulator before being named acting commissioner following Marty Makary's resignation. He will lead the agency on an interim basis while a permanent replacement is identified.
What is orforglipron and when might it be available?
Orforglipron is an oral GLP-1 receptor agonist developed by Eli Lilly that is taken as a daily pill rather than an injection. Phase 3 trial data has shown meaningful weight loss results. An FDA application is expected, though an approval timeline has not been confirmed.
Does FDA leadership affect drug pricing or insurance coverage for GLP-1s?
Directly, no. Drug pricing and insurance coverage are governed by manufacturers, pharmacy benefit managers, and payers rather than the FDA. However, FDA decisions on biosimilars and compounding policy can indirectly influence how much patients pay out of pocket.
What is retatrutide and how is it different from tirzepatide?
Retatrutide is an experimental drug also developed by Lilly that targets three hormone receptors: GLP-1, GIP, and glucagon. Tirzepatide targets GLP-1 and GIP. Early trial data for retatrutide showed very high rates of weight loss, but it is not yet FDA-approved and remains in clinical trials.